KBP-7018   Click here for help

GtoPdb Ligand ID: 9691

Synonyms: compound 3 [Huang et al., 2017]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: KBP-7018 is a multikinase inhibitor that simultaneously targets angiogenesis and fibrosis pathways [1]. It is considered a lead compound for potential therapeutic intervention in idiopathic pulmonary fibrosis. The principal molecular targets of KBP-7018 are the c-KIT, RET and PDGFR tyrosine kinases.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 100.21
Molecular weight 538.22
XLogP 2.94
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COC(=O)c1ccc2c(c1)NC(=O)C2=C(c1ccccc1)Nc1ccc2c(c1)CCN2C(=O)CN1CCOCC1
Isomeric SMILES COC(=O)c1ccc2c(c1)NC(=O)/C/2=C(/c1ccccc1)\Nc1ccc2c(c1)CCN2C(=O)CN1CCOCC1
InChI InChI=1S/C31H30N4O5/c1-39-31(38)22-7-9-24-25(18-22)33-30(37)28(24)29(20-5-3-2-4-6-20)32-23-8-10-26-21(17-23)11-12-35(26)27(36)19-34-13-15-40-16-14-34/h2-10,17-18,32H,11-16,19H2,1H3,(H,33,37)/b29-28-
InChI Key JVDJHTYIWQIOCA-ZIADKAODSA-N
Bioactivity Comments
KBP-7018 was more effective in a mouse pulmonary fibrosis model than the currently approved IPF kinase inhibitor drug nintedanib. KBP-7018 has no hERG liability (hERG IC50 >30000nM), which is in contrast to nintedanib (hERG IC50 2600nM). It also has improved oral bioavailability in comparison to nintedanib.
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
ret proto-oncogene Hs Inhibitor Inhibition 8.1 pIC50 - 1
pIC50 8.1 (IC50 7.6x10-9 M) [1]
KIT proto-oncogene, receptor tyrosine kinase Hs Inhibitor Inhibition 8.0 pIC50 - 1
pIC50 8.0 (IC50 1x10-8 M) [1]
platelet derived growth factor receptor beta Hs Inhibitor Inhibition 7.6 pIC50 - 1
pIC50 7.6 (IC50 2.5x10-8 M) [1]